Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $48.85 Consensus Target Price from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given a consensus recommendation of “Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, twelve have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $47.46.

A number of research analysts recently commented on the stock. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Scotiabank started coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, JPMorgan Chase & Co. cut their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 6,237 shares of company stock worth $77,760 over the last 90 days. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in Dyne Therapeutics by 0.3% during the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares in the last quarter. KBC Group NV increased its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the period. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Finally, Virtue Capital Management LLC boosted its stake in shares of Dyne Therapeutics by 4.4% during the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after buying an additional 981 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $12.08 on Friday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11. Dyne Therapeutics has a 1 year low of $11.18 and a 1 year high of $47.45. The business has a fifty day moving average of $13.60 and a 200-day moving average of $24.26.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.